Guardant Health, Inc. announced that its blood-based colorectal cancer screening product, Shield, was included in TIME’s annual list of the Best Inventions of 2024. This list features 200 innovations recognized for changing lives, with Shield specifically named to the Medical Care category.
TIME evaluated contenders based on originality, efficacy, ambition, and impact. AmirAli Talasaz, co-CEO and co-Founder of Guardant Health, highlighted that this recognition validates the company's vision to detect and characterize cancer at earlier stages with Shield, aiming to transform cancer detection and save lives.
The Shield test received FDA approval in July 2024 and Medicare reimbursement shortly thereafter. This inclusion on TIME's prestigious list underscores the product's groundbreaking nature and its potential to significantly impact public health by improving colorectal cancer screening rates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.